LAIYANG, China, July 9 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. (Nasdaq: JGBO) (the "Company" or"Jiangbo"), today announced that its management will present at the Global Hunter Securities China Investment Conference, which takes place July 11-13, 2010 at the St. Regis Hotel in San Francisco.
Location: Presentation Room 2, St. Regis Hotel, San Francisco
This event features approximately 100 China-based companies, most of which have shares that trade on U.S. exchanges. Companies from various sectors will make presentations to institutional investors during the conference, which serves as a forum for management teams to showcase their investment rationales, growth plans, current outlooks and positioning in China's growing marketplace. For more information about the conference and registration, please visit http://www.ghsecurities.com .
About Global Hunter Securities
Global Hunter Securities, LLC is a full service investment bank focusing on middle market corporate and institutional clients around the world. The firm provides insightful research, innovative capital raising and financial advisory and restructuring services supported by a sales and trading staff with world-wide reach. Global Hunter has offices in San Francisco, Los Angeles, New York, Houston, New Orleans, Newport Beach and Hong Kong, as well as a strong presence and reputation in mainland China. For more information about Global Hunter, please visit http://www.ghsecurities.com .
About Jiangbo Pharmaceuticals, Inc.
Jiangbo Pharmaceuticals is engaged in the research, development, production, marketing and sales of pharmaceutical products in China. The Company's operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong Province. Jiangbo produces both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. For additional information, please visit the Company's website ( http://www.jiangbopharma.com ).
For more information, please contact: Jiangbo Pharmaceuticals, Inc. Ms. Elsa Sung, CFO Tel: +1-954-903-9378 x2 Email: firstname.lastname@example.org Web: http:// www.jiangbopharma.com CCG Investor Relations Mr. Crocker Coulson, President Tel: +1-646-213-1915 Email: email@example.com Web: http://www.ccgirasia.com
SOURCE Jiangbo Pharmaceuticals, Inc.
Subscribe to our Free Newsletters!
Angiogenesis is the process of formation of new blood vessels from pre-existing blood vessels. It ...
Aniridia is a genetic eye disorder in which the iris is partially or entirely absent. It is ...
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...View All